Cover ImageSALE
市場調查報告書

亨丁頓舞蹈症治療藥的全球市場:2017年∼2021年

Global Huntington's Disease Therapeutics Market 2017-2021

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 317294
出版日期 內容資訊 英文 86 Pages
訂單完成後即時交付
價格
Back to Top
亨丁頓舞蹈症治療藥的全球市場:2017年∼2021年 Global Huntington's Disease Therapeutics Market 2017-2021
出版日期: 2017年08月02日 內容資訊: 英文 86 Pages
簡介

亨丁頓舞蹈症是進行性的神經退化性疾病,導致神經細胞及神經原的破壞。由於神經細胞的損傷,造成性格變化,及心情變動,易怒,改變行為方式等。這個疾病的治療藥市場,對於病理修飾藥的未滿足需求高,現在只有Xenazine唯一接受認證,可見到各種治療藥的非認證適應症的使用。還有由於AUSTEDO的市場引進,帶給市場成長很大的影響,將改變市場動態。全球亨丁頓舞蹈症治療藥市場,預計2017∼2021年以14.75%的年複合成長率成長。

本報告提供全球的亨丁頓舞蹈症治療藥的市場相關分析,市場概要和結構,市場規模趨勢(今後5年的預測值),各藥物等級、各地區的詳細趨勢,推動、市場的阻礙要素與其影響力,主要企業簡介,今後的市場機會等調查、考察。

第1章 摘要整理

第2章 分析範圍

第3章 市場分析技術

第4章 簡介

  • 市場概要

第5章 關於亨丁頓舞蹈症

第6章 市場環境

  • 市場概況
  • 市場規模與其預測
  • 波特的五力分析

第7章 開發平台

第8章 各藥物等級的市場分析

  • 各藥物等級市場
  • 抗多巴胺促效劑
  • 抗痙攣藥
  • 抗精神病藥
  • 抗憂鬱劑
  • 其他

第9章 各地區的分析

第10章 決策結構

第11章 促進市場成長的要素與課題

第12章 市場趨勢

第13章 供應商環境

  • 競爭方案

第14章 主要供應商分析

  • F. Hoffmann-La Roche
  • H. Lundbeck
  • Prana Biotechnology
  • Teva Pharmaceutical Industries
  • 其他卓越供應商

第15章 附錄

  • 簡稱集

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: IRTNTR14144

About Huntington's Disease Therapeutics

HD is an inherited condition that leads to destruction of nerve cells or neurons. The damage to nerve cells usually causes change in personality, mood swings, irritability and altered behavior. The global HD therapeutics market was witnessing a high unmet demand for disease modifying drug, in the presence of only one approved therapy, Xenazine, and the off-label use of various different therapeutics. The introduction of AUSTEDO in the market will have a significant impact on the market growth, thereby changing the market dynamics.

Technavio's analysts forecast the global huntington's disease therapeutics market to grow at a CAGR of 14.75% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global huntington's disease therapeutics market for 2017-2021. To calculate the market size, the report considers sales of branded, generic, and off label drugs.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Huntington's Disease Therapeutics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • F. Hoffmann-La Roche
  • H. Lundbeck
  • Prana Biotechnology
  • Teva Pharmaceutical Industries

Other Prominent Vendors

  • Intellect Neurosciences
  • Horizon Pharma
  • Sangamo Therapeutics
  • Vertex Pharmaceuticals

Market driver

  • Early onset of disease symptoms, increases the demand for HD therapeutics
  • For a full, detailed list, view our report

Market challenge

  • Increase in alternative programs for management of mental disorders
  • For a full, detailed list, view our report

Market trend

  • Advances in biomedical sciences
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

  • Market outline

PART 05: HD: An introduction

PART 06: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 07: Pipeline

PART 08: Market segmentation by drug-class

  • Market scenario by drug-class
  • Antidopaminergics
  • Anticonvulsants
  • Antipsychotics
  • Antidepressants
  • Others

PART 09: Geographical segmentation

  • Market segmentation by geography
  • HD therapeutics market in Americas
  • HD therapeutics market in EMEA
  • HD therapeutics market in APAC

PART 10: Decision framework

PART 11: Drivers and challenges

  • Market drivers
  • Market challenges

PART 12: Market trends

  • Advances in biomedical sciences
  • Focus on regenerative therapies for mental disorders
  • Rising public interest toward mental health

PART 13: Vendor landscape

  • Competitive scenario

PART 14: Key vendor analysis

  • F. Hoffmann-La Roche
  • H. Lundbeck
  • Prana Biotechnology
  • Teva Pharmaceutical Industries
  • Other prominent vendors

PART 15: Appendix

  • List of abbreviations

List of Exhibits

  • Exhibit 01: Parts of brain affected by HD
  • Exhibit 02: Key facts about HD
  • Exhibit 03: Prevalence and incidence of HD
  • Exhibit 04: Neurotransmitter involved in pathogenesis of HD
  • Exhibit 05: Market snapshot
  • Exhibit 06: Global HD therapeutics market 2016-2021 ($ millions)
  • Exhibit 07: Opportunity analysis of global HD therapeutics market
  • Exhibit 08: Five forces analysis
  • Exhibit 09: Pipeline landscape based on number of molecules 2016
  • Exhibit 10: HD: Key clinical trials
  • Exhibit 11: Segmentation of global HD therapeutics market by drug-class
  • Exhibit 12: Global HD therapeutics market share by drug-class
  • Exhibit 13: Antidopaminergics used in HD
  • Exhibit 14: Uses and side-effects of antidopaminergics
  • Exhibit 15: Global HD therapeutics market by antidopaminergics 2016-2021 ($ millions)
  • Exhibit 16: Pharmacologic approach for the treatment of chorea
  • Exhibit 17: Anticonvulsants used in HD
  • Exhibit 18: Uses and side-effects of anticonvulsants
  • Exhibit 19: Global HD therapeutics market by anticonvulsants 2016-2021 ($ millions)
  • Exhibit 20: Antipsychotics used in HD
  • Exhibit 21: Uses and side-effects of antipsychotics
  • Exhibit 22: Global HD therapeutics market by antipsychotics 2016-2021 ($ millions)
  • Exhibit 23: Symptoms of depression associated with HD
  • Exhibit 24: Global HD therapeutics market by antidepressants 2016-2021 ($ millions)
  • Exhibit 25: Symptoms of mania associated with HD
  • Exhibit 26: Global HD therapeutics market share by geography 2016 and 2021
  • Exhibit 27: Global HD therapeutics market revenue by geography 2016-2021
  • Exhibit 28: Global HD therapeutics market share by geography 2016-2021
  • Exhibit 29: HD therapeutics market scenario in different geographies
  • Exhibit 30: Market scenario in Americas
  • Exhibit 31: HD therapeutics market in Americas 2016-2021 ($ millions)
  • Exhibit 32: Market scenario in EMEA
  • Exhibit 33: HD therapeutics market in EMEA 2016-2021 ($ millions)
  • Exhibit 34: Market scenario in APAC
  • Exhibit 35: HD therapeutics market in APAC 2016-2021 ($ millions)
  • Exhibit 36: Planned clinical trials of iPS cell-based therapies
  • Exhibit 37: Competitive structure analysis of global HD therapeutics market 2016
  • Exhibit 38: F. Hoffmann-La Roche: Key highlights
  • Exhibit 39: F. Hoffmann-La Roche: Strength assessment
  • Exhibit 40: F. Hoffmann-La Roche: Strategy assessment
  • Exhibit 41: F. Hoffmann-La Roche: Opportunity assessment
  • Exhibit 42: H. Lundbeck: Key highlights
  • Exhibit 43: H. Lundbeck: Strength assessment
  • Exhibit 44: H. Lundbeck: Strategy assessment
  • Exhibit 45: H. Lundbeck: Opportunity assessment
  • Exhibit 46: Prana Biotechnology: Key highlights
  • Exhibit 47: Prana Biotechnology: Strength assessment
  • Exhibit 48: Prana Biotechnology: Strategy assessment
  • Exhibit 49: Prana Biotechnology: Opportunity assessment
  • Exhibit 50: Teva Pharmaceuticals: Key highlights
  • Exhibit 51: Teva Pharmaceuticals: Strength assessment
  • Exhibit 52: Teva Pharmaceuticals: Strategy assessment
  • Exhibit 53: Teva Pharmaceuticals: Opportunity assessment
Back to Top